Mereo BioPharma Group PLC reports results for the quarter ended March 31 - Earnings Summary

Mereo BioPharma

13/05/2025 13:58

Mereo BioPharma Group PLC MREO.OQ reported a quarterly adjusted loss of 8 pence​​ per share for the quarter ended March 31, lower than the same quarter last year, when the company reported breakeven earnings per share.  The mean expectation of seven analysts for the quarter was for a loss of one penny per share. Wall Street expected results to range from -7 pence to 5 pence per share.

Reported revenue was zero​; analysts expected £14.50 million.

Mereo BioPharma Group PLC's reported EPS for the quarter was a loss of 8 pence​.

The company reported a quarterly loss of £10.23 million.

Mereo BioPharma Group PLC shares had risen by 11.1% this quarter and lost 28.6% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had fallen by about 149.3% in the last three months.​

In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 9 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "strong buy"

Wall Street's median 12-month price target for Mereo BioPharma Group PLC is $7.00

This summary was machine generated from LSEG data May 13 at 12:58 p.m. UTC. ​All figures in pounds unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Mar. 31 2025
-0.01
-0.08
Missed
Dec. 31 2024
-0.01
-0.04
Missed
Sep. 30 2024
-0.01
-0.08
Missed
Jun. 30 2024
-0.01
-0.08
Missed